These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders]. Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375 [TBL] [Abstract][Full Text] [Related]
6. Iodine-123 iodobenzofuran (I-123 IBF) SPECT in patients with parkinsonism. Nakabeppu O; Nakajo M; Mitsuda M; Tsuchimochi S; Tani A; Osame M Ann Nucl Med; 1999 Dec; 13(6):447-52. PubMed ID: 10656283 [TBL] [Abstract][Full Text] [Related]
7. [Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs]. Hierholzer J; Castelli L; Cordes M; Schelosky L; Poewe W; Felix R Radiol Med; 1996 Mar; 91(3):207-10. PubMed ID: 8628932 [TBL] [Abstract][Full Text] [Related]
8. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Kim YJ; Ichise M; Ballinger JR; Vines D; Erami SS; Tatschida T; Lang AE Mov Disord; 2002 Mar; 17(2):303-12. PubMed ID: 11921116 [TBL] [Abstract][Full Text] [Related]
9. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. Knable MB; Jones DW; Coppola R; Hyde TM; Lee KS; Gorey J; Weinberger DR J Nucl Med; 1995 Jul; 36(7):1216-25. PubMed ID: 7790947 [TBL] [Abstract][Full Text] [Related]
10. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. Hierholzer J; Cordes M; Venz S; Schelosky L; Harisch C; Richter W; Keske U; Hosten N; Mäurer J; Poewe W; Felix R J Nucl Med; 1998 Jun; 39(6):954-60. PubMed ID: 9627325 [TBL] [Abstract][Full Text] [Related]
14. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. Seppi K; Schocke MF; Donnemiller E; Esterhammer R; Kremser C; Scherfler C; Diem A; Jaschke W; Wenning GK; Poewe W Mov Disord; 2004 Dec; 19(12):1438-45. PubMed ID: 15390073 [TBL] [Abstract][Full Text] [Related]
15. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. van Royen E; Verhoeff NF; Speelman JD; Wolters EC; Kuiper MA; Janssen AG Arch Neurol; 1993 May; 50(5):513-6. PubMed ID: 8489409 [TBL] [Abstract][Full Text] [Related]
19. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT. Schelosky L; Hierholzer J; Wissel J; Cordes M; Poewe W Mov Disord; 1993 Oct; 8(4):453-8. PubMed ID: 8232354 [TBL] [Abstract][Full Text] [Related]